Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) Net Margin (2018 - 2025)

Historic Net Margin for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to 78.41%.

  • Arcturus Therapeutics Holdings' Net Margin fell 618400.0% to 78.41% in Q3 2025 from the same period last year, while for Sep 2025 it was 68.35%, marking a year-over-year decrease of 293200.0%. This contributed to the annual value of 53.14% for FY2024, which is 353200.0% down from last year.
  • Latest data reveals that Arcturus Therapeutics Holdings reported Net Margin of 78.41% as of Q3 2025, which was down 618400.0% from 32.44% recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Net Margin registered a high of 74.02% during Q4 2022, and its lowest value of 2711.14% during Q1 2021.
  • Over the past 5 years, Arcturus Therapeutics Holdings' median Net Margin value was 78.41% (recorded in 2025), while the average stood at 548.61%.
  • In the last 5 years, Arcturus Therapeutics Holdings' Net Margin crashed by -23535500bps in 2021 and then skyrocketed by 26050700bps in 2022.
  • Arcturus Therapeutics Holdings' Net Margin (Quarter) stood at 649.72% in 2021, then soared by 111bps to 74.02% in 2022, then tumbled by -151bps to 37.85% in 2023, then plummeted by -248bps to 131.8% in 2024, then soared by 41bps to 78.41% in 2025.
  • Its Net Margin was 78.41% in Q3 2025, compared to 32.44% in Q2 2025 and 47.91% in Q1 2025.